News

CMN Weekly (19 April 2024) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Apr. 19, 2024
News

#CRISPRMED24

Top picks

Research

Industry

Detection

Reviews

Perspectives

  • A feature in Nature Biotechnology highlights the competitive IP landscape in prime editing, including the prime editing patents secured by Liu's lab. These patents cover methods for site-specific DNA modifications using a combination of Cas9 and reverse transcriptase. These patents set a precedent that may require newer technologies to navigate carefully to avoid infringement, influencing strategic decisions like mergers and licensing in the biotech industry to secure access to crucial patented technologies. A list of current prime editing patents is available.
  • A feature in Nature Reviews Drug Discovery describes the emergence of RNA-editing therapies. Recently, at least three RNA-editing drugs have reached clinical trials or received approval to begin trials. These therapies offer the potential for precise genetic modifications without permanent changes to the DNA, providing a flexible approach for treating a variety of conditions, including cancer, pain, and high cholesterol.

Ooh, aah, wow

News from CRISPR Medicine News

  • Hopefully, you have already signed up for the CRISPR Medicine Conference 2024, which we proudly present next week in Copenhagen. More than 550 attendees will gather to listen to over 50 talks and watch 100+ posters. We are looking forward to seeing you!

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (19 April 2024) - Your Weekly CRISPR Medicine News
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Chronic Hepatitis B, HBV, (NCT06680232)
Sponsors:
Precision BioSciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine